NewsRelease
PatentCites AlbuSorb™ for ApoCIII analysis in diabetics
MONMOUTHJUNCTION, NJ,February22, 2017 -- Biotech Support Group reports on a recent patent usingAlbuSorb™as part of the description of the invention.
Thecitation is:
Berggren,Per-olof, and Lisa Juntti-berggren. "Methods for treating and/orlimiting development of diabetes." U.S. Patent No.20,170,037,118. 9 Feb. 2017.
Inbrief, the inventors disclose methodsand compositions for limiting development of and/or treatingdiabetes, involving compounds of formula A-B, wherein A is apancreatic β cell targeting moiety, and B is an inhibitor ofexpression and/or activity of Apolipoprotein CIII (apoCIII), proteinkinase A (PKA), Src kinase, and/or β1 integrin. The patent states “…toevaluate the levels of apoCIII in sera, albumin is removed from serumsamples using standard techniques, such as … AlbuSorb™(Biotech Support Group)”.The inventors describe that ApoCIIIcan be identified using any suitable technique, including but notlimited to MALDI mass spectrometry.
“Thisreference shows that while apoCIII is a hydrophobic protein and canoften bind non-specifically, AlbuSorb™can nevertheless be used in its analysis.” states Swapan Roy,Ph.D., President and Founder of Biotech Support Group.
Formore information visit: AlbuSorb™Albumin Depletion Kit at
http://www.biotechsupportgroup.com/AlbuSorb-Albumin-Depletion-Kit-p/a185.htm
AboutBiotech Support Group LLC
Convergingwith cultural and technological disruptions forthcoming inhealthcare, Biotech Support Group develops methods for cost effectiveand efficient sample prep essential for these expanding markets.Following a tiered business strategy, the company continues itsgrowth in the consumable research products area supporting therapidly expanding installation of LC-MS instrument and computationalinfrastructure. For this market, key products include: AlbuVoid™and AlbuSorb™ for albumin depletion, Cleanascite™ forlipid adsorption, HemogloBind™ and HemoVoid™ forhemoglobin removal, and NuGel™ for functional proteomics. Fromthese innovations, the company has acquired knowledgebase andbiomarker intellectual property assets that support discoveries ofprotein markers from blood, with special emphasis on early detectionand personalized medical decisions for cancer patients. For moreinformation, go tohttp://www.biotechsupportgroup.com
Contact:
MatthewKuruc 732-274-2866